PICX CAR-T therapy for relapsed or hard-to-treat multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called PICX CAR-T, a type of immune cell therapy, for multiple myeloma that has come back or not responded well to at least two prior treatments. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your multiple myeloma has gotten worse after at least two standard treatments, or it came back within 18 months after your first treatment
- You have measurable signs of the disease, like certain protein levels in blood or urine
- You are generally well enough to be out of bed and active (ECOG score 0-2)
- Your blood counts and organ functions (kidney, liver, heart, lungs) meet minimum levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to treatment and has spread outside the bone marrow (extramedullary disease). The goal is to see if this dual-target approach can attack the cancer more effectively.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests a new type of CAR-T cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for people whose multiple myeloma has come back or not responded after at least three prior treatments.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
Hear when a new Relapsed or Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.